Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 57.58% | 0.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 60.97% | -6.35% | |||
| Operating Income | -60.97% | 6.35% | |||
| Income Before Tax | -59.48% | 6.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -59.48% | 6.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -59.48% | 6.10% | |||
| EBIT | -60.97% | 6.35% | |||
| EBITDA | -61.20% | 6.53% | |||
| EPS Basic | -50.53% | 5.94% | |||
| Normalized Basic EPS | -48.33% | 4.76% | |||
| EPS Diluted | -50.53% | 5.94% | |||
| Normalized Diluted EPS | -48.33% | 4.76% | |||
| Average Basic Shares Outstanding | 6.37% | 0.00% | |||
| Average Diluted Shares Outstanding | 6.37% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||